Abbott Laboratories (ABTT34.SA)
São Paulo - São Paulo Delayed price. Currency in BRL
Add to watchlist
At close: 10:35AM BRT
| Previous close | 44.80 |
| Open | 0.00 |
| Bid | 44.34 x 0 |
| Ask | 44.84 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 429 |
| Market cap | 957.685B |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 32.70 |
| EPS (TTM) | 1.37 |
| Earnings date | 18 July 2024 - 22 July 2024 |
| Forward dividend & yield | 0.64 (1.43%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
ZacksIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.